Sep 18, 2026

Innate Pharma (IPHA) reported its Q2 2026 earnings, highlighting significant progress in its oncology pipeline, particularly with lacutamab and its proprietary antibody-drug conjugate (ADC) technology. The company secured capital through a partnership with Sobi and an equity offering, extending its operational runway into early 2028. Key catalysts include a Phase 3 readout for monalizumab and initial clinical data for its Nectin-4 ADC program, with accelerated approval filings anticipated for lacutamab in Sezary Syndrome in late 2027.